Publication

Bicalutamide 150 mg as adjuvant to radiotherapy significantly increases progression-free survival in early prostate cancer.

Payne H, Tyrrell CJ, See WA, McLeod DG, Wirth MP, Iversen P, Garside L.

Int J Radiat Oncol Biol Phys 2003